Interleukin-21 enhances NK cell activation in response to antibody-coated targets

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 120-129

  Roda, Julie M ^a   Parihar, Robin ^a   Lehman, Amy ^a   Mani, Aruna ^a   Tridandapani, Susheela ^a   Carson III, William E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 21; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; RANTES; STAT1 PROTEIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVATION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 33745298650     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.120     Document Type: Article

References (35)

1. Robertson, M. J., and J. Ritz. 1990. Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438.
2. Sliwkowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26: 60-70.
3. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
4. Strengell, M., S. Matikainen, J. Siren, A. Lehtonen, D. Foster, I. Julkunen, and T. Sareneva. 2003. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. 170: 5464-5469.
5. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63.
6. Wang, G., M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J. Leonard, and P. Hwu. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022.
7. Ma, H. L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perform but are independent of IFN-γ. J. Immunol. 171: 608-615.
8. Brady, J., Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172: 2048-2058.
9. Di Carlo, E., A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini. 2004. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547.
10. Anegon, I., M. C. Cuturi, G. Trinchieri, and B. Perussia. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167: 452-472.
11. Oliva, A., A. L. Kinter, M. Vaccarezza, A. Rubbert, A. Catanzaro, S. Moir, J. Monaco, L. Ehler, S. Mizell, R. Jackson, et al. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102: 223-231.
12. Carson, W. E., R. Parihar, M. J. Lindemann, N. Personeni, J. Dierksheide, N. J. Meropol, J. Baselga, and M. A. Caligiuri. 2001. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31: 3016-3025.
13. Parihar, R., J. Dierksheide, Y. Hu, and W. E. Carson. 2002. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest. 110: 983-992.
14. Roda, J. M., R. Parihar, and W. E. Carson, 3rd. 2005. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 175: 1619-1627.
15. Leonard, W. J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5: 688-698.
16. Mohan, K., Z. Ding, J. Hanly, and T. B. Issekutz. 2002. IFN-γ-inducible T cell α chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: differential regulation by IFN-γ and TNF-α. J. Immunol. 168: 6420-6428.
17. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61: 246-257.
18. Megjugorac, N. J., H. A. Young, S. B. Amrute, S. L. Olshalsky, and P. Fitzgerald-Bocarsly. 2004. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J. Leukocyte Biol. 75: 504-514.
19. Lesinski, G. B., S. V. Kondadasula, T. Crespin, L. Shen, K. Kendra, M. Walker, and W. E. Carson, 3rd. 2004. Multiparametric flow cytometric analysis of interpatient variation in STAT1 phosphorylation following interferon α immunotherapy. J. Natl. Cancer Inst. 96: 1331-1342.
20. Suk, K., I. Chang, Y. H. Kim, S. Kim, J. Y. Kim, H. Kim, and M. S. Lee. 2001. Interferon γ (IFNγ) and tumor necrosis factor α synergism in ME-180 cervical cancer cell apoptosis and necrosis: IFNγ inhibits cytoprotective NF-γB through STAT1/IRF-1 pathways. J. Biol. Chem. 276: 13153-13159.
21. Shin, E. C., J. M. Ahn, C. H. Kim, Y. Choi, Y. S. Ahn, H. Kim, S. J. Kim, and J. H. Park. 2001. IFN-γ induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int. J. Cancer 93: 262-268.
22. Park, S. Y., J. W. Seol, Y. J. Lee, J. H. Cho, H. S. Kang, I. S. Kim, S. H. Park, T. H. Kim, J. H. Yim, M. Kim, et al. 2004. IFN-γ enhances TRAIL-induced apoptosis through IRF-1. Eur. J. Biochem. 271: 4222-4228.
23. Curcio, C., E. Di Carlo, R. Clynes, M. J. Smyth, K. Boggio, E. Quaglino, M. Spadaro, M. P. Colombo, A. Amici, P. L. Lollini, et al. 2003. Nonredundant roles of antibody, cytokines, and perform in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111: 1161-1170.
24. Parihar, R., P. Nadella, A. Lewis, R. Jensen, C. De Hoff, J. E. Dierksheide, A. M. VanBuskirk, C. M. Magro, D. C. Young, C. L. Shapiro, and W. E. Carson III. 2004. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin. Cancer Res. 10: 5027-5037.
25. Carson, W. E. 2005. Phase I trial of interleukin-12 with trastuzumab and paclitaxel in HER2-overexpressing malignancies: J. Clin. Oncol. 23: 173 S. (Abstr.).
26. Roda, J. M., R. Parihar, C. Magro, G. J. Nuovo, S. Tridandapani, and W. E. Carson III. 2006. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 66: 517-526.
27. Kasaian, M. T., M. J. Whitters, L. L. Carter, L. D. Lowe, J. M. Jussif, B. Deng, K. A. Johnson, J. S. Witek, M. Senices, R. F. Konz, et al. 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569.
28. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173: 900-909.
29. + T cell expansion and function. J. Exp. Med. 201: 139-148.
30. Asao, H., C. Okuyama, S. Kumaki, N. Ishii, S. Tsuchiya, D. Foster, and K. Sugamura. 2001. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167: 1-5.
31. Ting, A. T., C. J. Dick, R. A. Schoon, L. M. Karnitz, R. T. Abraham, and P. J. Leibson. 1995. Interaction between lck and syk family tyrosine kinases in Fey receptor-initiated activation of natural killer cells. J. Biol. Chem. 270: 16415-16421.
32. Manciulea, M., H. Rabinowich, A. Sulica, W. C. Lin, T. L. Whiteside, A. DeLeo, R. B. Herberman, and S. J. Corey. 1996. Divergent phosphotyrosine signaling via FcγRIIIA on human NK cells. Cell. Immunol. 167: 63-71.
33. Pelletier, M., A. Bouchard, and D. Girard. 2004. In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. 173: 7521-7530.
34. Lo, R. K., H. Wise, and Y. H. Wong. 2005. Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. Cell. Signal. 18: 307-317.
35. Lo, R. K., H. Cheung, and Y. H. Wong. 2003. Constimtively active Gα16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J. Biol. Chem. 278: 52154-52165.